Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
2.72(c) 2.67(c) 2.51(c) 2.52(c) 2.53 Last
271 859 522 391 513 635 354 111 94 094 Volume
-0.00% -1.84% -5.99% +0.40% +0.40% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -19,9 M
Net income 2017 -19,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,05 M
EBIT 2018 -23,6 M
Net income 2018 -23,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 26,5x
Capitalization 213 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
10/16 Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
09/01 CATALYST PHARMACEUTICALS : Provides Update on the Status of its Firdapse Develop..
08/31 CATALYST PHARMACEUTICALS : Provides Update on the Status of its Firdapse Develop..
08/30 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
08/30 Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Develo..
08/10 CATALYST PHARMACEUTICALS INC : Investor Network: Catalyst Pharmaceuticals, Inc. ..
08/09 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
08/09 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
08/09 CATALYST PHARMACEUTICALS : Announces Second Quarter 2017 Financial Results and P..
08/09 CATALYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
More news
Sector news : Bio Therapeutic Drugs
06:58p Regeneron-Sanofi drug succeeds mid-stage study
06:39pDJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
06:48aDJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum  
10/16$CPRX Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum F.. 
10/16Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum  
10/12Catalyst Pharmaceuticals, Inc. $CPRX Downgraded to “Sell” at Zacks Investment.. 
10/11$CPRX - Catalyst Pharmaceuticals, Inc. #CPRX Rating Lowered to Sell at Zacks .. 
More tweets
Qtime:493
News from SeekingAlpha
08/10 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Resul..
08/09 Catalyst Pharmaceutical beats by $0.01
06/07 Catalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare ..
05/11 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Resul..
05/10 Catalyst Pharmaceutical EPS in-line
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,44 $
Spread / Average Target 116%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC139.05%213
GILEAD SCIENCES11.65%104 409
REGENERON PHARMACEUTICALS20.67%47 756
VERTEX PHARMACEUTICALS107.56%39 003
ACTELION23.24%29 757
GENMAB22.08%13 881